Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validating Ultrasound Biomarkers for VOD/SOS in Pediatric HCT
NCT03963999Phase 4Withdrawn
- Sponsor
- Children's Mercy Kansas City
- Start
- Apr 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sulfur hexafluoride in hepatic veno-occlusive disease (HVOD), sponsored by Children's Mercy Kansas City. Primary endpoints: Sensitivity and Specificity of US (grayscale, Doppler and SWE) for Diagnosis and Severity Grading for SOS/VOD, Sensitivity and Specificity of CEUS for Diagnosis and Severity Grading for SOS/VOD and 1 more. Planned start Apr 2020; status: withdrawn.
02
Drugs
sulfur hexafluoride
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on NCT03963999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963999.